RZLTRezolute, Inc.
- GlobeNewswire
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating ...
- Analyst Upgrades
This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Analysts upgraded NetApp, Humana, Corteva, Afya, with price-target changes for four stocks. ...
- Analyst Upgrades
Lake Street Maintains Buy on Rezolute, Raises Price Target to $12
Lake Street analyst Daniel Brims maintains Rezolute with a Buy and raises the price target from $9 to $12. ...
- Analyst Upgrades
Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15
Citizens analyst Jason N. Butler maintains Rezolute with a Market Outperform and raises the price target from $11 to $15. ...
- Analyst Upgrades
This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names. ...
- Analyst Upgrades
Cantor Fitzgerald Upgrades Rezolute to Overweight
Cantor Fitzgerald analyst Pete Stavropoulos upgrades Rezolute from Neutral to Overweight. ...
- Analyst Upgrades
Lake Street Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $9
Lake Street analyst Daniel Brims initiates coverage on Rezolute with a Buy rating and announces Price Target of $9. ...
- Analyst Upgrades
This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded STAA, NFLX, SFIX, with ratings moving toward Buy or Neutral and mixed price-target changes. ...
- Analyst Upgrades
Craig-Hallum Upgrades Rezolute to Buy, Raises Price Target to $7
Craig-Hallum analyst Albert Lowe upgrades Rezolute from Hold to Buy and raises the price target from $4 to $7. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Rezolute, Raises Price Target to $10
HC Wainwright & Co. analyst Douglas Tsao maintains Rezolute with a Buy and raises the price target from $5 to $10. ...
- GlobeNewswire
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction ...
- GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia ...
- GlobeNewswire
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia ...
- GlobeNewswire
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in congenital HI and a case ...
- Analyst Upgrades
Guggenheim Maintains Buy on Rezolute, Raises Price Target to $11
Guggenheim analyst Debjit Chattopadhyay maintains Rezolute with a Buy and raises the price target from $6 to $11. ...
- Earnings Call Transcripts
Jeffries Global Healthcare Conference in New York - REZOLUTE INC
Hi, everyone. My name is Morrie Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome Nevin Charles-Alam, the founder and CEO of Resolute. It's a late-stage ultra-rare disease company focused on ...
- GlobeNewswire
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a ...
- Analyst Upgrades
Maxim Group Maintains Buy on Rezolute, Raises Price Target to $14
Maxim Group analyst Jason McCarthy maintains Rezolute with a Buy and raises the price target from $10 to $14. ...
- Analyst Upgrades
Citizens Upgrades Rezolute to Market Outperform, Announces $11 Price Target
Citizens analyst Jason N. Butler upgrades Rezolute from Market Perform to Market Outperform and announces $11 price target. ...
- Analyst Upgrades
Wedbush Maintains Outperform on Rezolute, Raises Price Target to $6
Wedbush analyst Yun Zhong maintains Rezolute with a Outperform and raises the price target from $5 to $6. ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $5 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute with a Buy and maintains $5 price target. ...
- GlobeNewswire
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study's primary endpoint Topline results for the fully enrolled open-label study are expected in the second half of 2026 ...
- Analyst Upgrades
Maxim Group Maintains Buy on Rezolute, Raises Price Target to $10
Maxim Group analyst Jason McCarthy maintains Rezolute with a Buy and raises the price target from $4 to $10. ...
- GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of ...
- GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of ...